- Report
- December 2019
- 139 Pages
United States
From €2892EUR$3,000USD£2,474GBP
- Report
- August 2022
- 218 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- January 2024
- 72 Pages
From €3808EUR$3,950USD£3,257GBP
- Report
- September 2022
- 70 Pages
Global
From €3808EUR$3,950USD£3,257GBP
- Report
- September 2022
- 135 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- August 2022
- 109 Pages
Global
From €3808EUR$3,950USD£3,257GBP
- Report
- January 2022
- 200 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- January 2022
- 60 Pages
Global
From €3808EUR$3,950USD£3,257GBP
- Report
- March 2023
- 164 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- January 2019
- 95 Pages
Global
From €4146EUR$4,300USD£3,546GBP
- Drug Pipelines
- August 2018
- 171 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- August 2022
United States
From €1870EUR$1,940USD£1,600GBP
- Report
- August 2022
Global
From €1051EUR$1,090USD£899GBP
- Report
- August 2021
Global
From €3847EUR$3,990USD£3,290GBP
- Report
- August 2021
Europe
From €3297EUR$3,420USD£2,820GBP
- Report
- February 2021
Global
From €2854EUR$2,960USD£2,441GBP
- Clinical Trials
- January 2022
- 442 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Clinical Trials
- October 2021
- 427 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Clinical Trials
- October 2020
- 379 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- September 2020
- 43 Pages
Global
From €3852EUR$3,995USD£3,294GBP
The Pulmonary Fibrosis Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat pulmonary fibrosis, a chronic and progressive lung disease. These drugs are used to reduce symptoms, slow the progression of the disease, and improve quality of life. Common treatments include corticosteroids, immunosuppressants, and antifibrotic agents. In some cases, lung transplantation may be recommended.
The Pulmonary Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of these companies include Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Novartis, and Vertex Pharmaceuticals. Show Less Read more
